Targeted medications can be used to treat HER2-overexpress breast cancer and improve its prognosis (7–9); however, triple-negative breast cancer is associated with a worse prognosis and shorter survival period (10, 11), partly because of the lack of effective drugs (12). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.